Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of XZP-3621 versus crizotinib in ALK-positive advanced non-small cell lung cancer
CTR20213198Phase 3Active
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dirozalkib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Xuanzhu Biopharmaceutical. Primary endpoint: Investigator-assessed progression-free survival. Started Jan 2022; status: active.
02
Drugs
dirozalkib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20213198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213198.